Compare NEXA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | ABCL |
|---|---|---|
| Founded | 1956 | 2012 |
| Country | Luxembourg | Canada |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | NEXA | ABCL |
|---|---|---|
| Price | $14.43 | $4.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $6.20 | ★ $7.75 |
| AVG Volume (30 Days) | 843.7K | ★ 4.8M |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,839,970,000.00 | $35,325,000.00 |
| Revenue This Year | $5.51 | $25.45 |
| Revenue Next Year | $3.70 | $10.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.95 | ★ 7.17 |
| 52 Week Low | $4.44 | $1.89 |
| 52 Week High | $13.87 | $6.52 |
| Indicator | NEXA | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 82.77 | 52.05 |
| Support Level | $12.24 | $3.92 |
| Resistance Level | $9.82 | $4.85 |
| Average True Range (ATR) | 0.65 | 0.34 |
| MACD | 0.28 | 0.02 |
| Stochastic Oscillator | 100.00 | 49.95 |
Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.